RT Journal Article
SR Electronic
T1 Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.13.21256639
DO 10.1101/2021.05.13.21256639
A1 Paul T. Heath
A1 Eva P. Galiza
A1 David Neil Baxter
A1 Marta Boffito
A1 Duncan Browne
A1 Fiona Burns
A1 David R. Chadwick
A1 Rebecca Clark
A1 Catherine Cosgrove
A1 James Galloway
A1 Anna L. Goodman
A1 Amardeep Heer
A1 Andrew Higham
A1 Shalini Iyengar
A1 Arham Jamal
A1 Christopher Jeanes
A1 Philip A. Kalra
A1 Christina Kyriakidou
A1 Daniel F. McAuley
A1 Agnieszka Meyrick
A1 Angela M. Minassian
A1 Jane Minton
A1 Patrick Moore
A1 Imrozia Munsoor
A1 Helen Nicholls
A1 Orod Osanlou
A1 Jonathan Packham
A1 Carol H. Pretswell
A1 Alberto San Francisco Ramos
A1 Dinesh Saralaya
A1 Ray P. Sheridan
A1 Richard Smith
A1 Roy L. Soiza
A1 Pauline A. Swift
A1 Emma C. Thomson
A1 Jeremy Turner
A1 Marianne Elizabeth Viljoen
A1 Gary Albert
A1 Iksung Cho
A1 Filip Dubovsky
A1 Greg Glenn
A1 Joy Rivers
A1 Andreana Robertson
A1 Kathy Smith
A1 Seth Toback
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.05.13.21256639.abstract
AB Background Covid-19 vaccines are urgently needed, especially against emerging variants. NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 rS) nanoparticle vaccine containing trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant.Methods A phase 3, randomized, observer-blinded, placebo-controlled trial was conducted in adults 18-84 years old who received two intramuscular 5-µg doses, 21 days apart, of NVX-CoV2373 or placebo (1:1) across 33 sites in the United Kingdom. The primary efficacy endpoint was virologically confirmed symptomatic Covid-19 with onset 7 days after second vaccination in serologically negative participants.Results A total of 15,187 participants were randomized, of whom 7569 received NVX-CoV2373 and 7570 received placebo; 27.2% were 65 years or older, 44.7% had comorbidities and 4.2% had baseline serological evidence of SARS-CoV-2. There were 10 cases of Covid-19 among NVX-CoV2373 recipients and 96 cases among placebo recipients, with symptom onset at least 7 days after second vaccination; NVX-CoV2373 was 89.7% (95% confidence interval, 80.2 to 94.6) effective in preventing Covid-19, with no hospitalizations or deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of 96.4% (73.8 to 99.5) and 86.3% (71.3 to 93.5) against the prototype strain and B.1.1.7 variant, respectively. Vaccine efficacy was similar across subgroups, including participants with comorbidities and those ≥65 years old. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups.Conclusion A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.1.7 variant, and had a reassuring safety profile.(Funded by Novavax, Inc. EudraCT number, 2020-004123-16).Competing Interest StatementDisclosure forms provided by the authors will be available with the full text of this article upon publication.Clinical TrialNCT04583995Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04583995 https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB Funding StatementFunded by Novavax, Inc. EudraCT number, 2020-004123-16Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the North West-Greater Manchester Central Research Ethics Committee (Ref 20/NW/03/99) and was performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines (see protocol in the Supplementary Appendix).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLimited data will be available on the following websites: https://clinicaltrials.gov/ct2/show/NCT04583995 https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB